Greetings. Welcome to Sutro Biopharma R&D Day 2025 Conference Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Jane Chung, CEO.

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

Samsung said Tuesday it had decided to invest in Phrontline Biopharma, a Chinese biotechnology firm with an antibody-drug conjugate platform and pipeline, through Samsung Life Science Fund. Samsung ...

- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - ...

VARCES, France (AP) — President Emmanuel Macron on Thursday unveiled a new program meant to bolster France’s armed forces by training thousands of volunteers aged 18 and 19 starting next year, part of ...

The U.S. Border Patrol is monitoring millions of American drivers nationwide in a secretive program to identify and detain people whose travel patterns it deems suspicious. (AP video: Marshall Ritzel) ...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...

Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.